List Results
Refine Search
Results by Topic
Results on Map
Search Details
Found 1113 studies with search of: (lymphoma OR CLL [CONDITION ]) AND NOT myeloma [CONDITION] | Open Studies
Include studies that are not seeking new volunteers.
  Display Options
Rank Status Study
1 Recruiting Study of AMD3100 and Rituximab in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: Chronic Lymphocytic Leukemia (CLL);   Small Lymphocytic Lymphoma (SLL)
Intervention: Drug: Plerixafor
2 Recruiting Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL
Conditions: NHL;   Lymphoma, Non-Hodgkin;   Lymphoma, B-Cell;   Lymphoma, Follicular;   Lymphoma, Intermediate-Grade;   Lymphoma, Large-Cell;   Lymphoma, Low-Grade;   Lymphoma, Mixed-Cell;   Lymphoma, Small-Cell;   Leukemia, Lymphocytic, Chronic;   Leukemia, B-Cell, Chronic;   Leukemia, Prolymphocytic;   Leukemia, Small Lymphocytic;   Lymphoma, Small Lymphocytic;   Lymphoma, Lymphoplasmacytoid, CLL;   Lymphoplasmacytoid Lymphoma, CLL;   CLL;   SLL
Intervention: Biological: veltuzumab
3 Recruiting Pilot Study for Patients With Chemotherapy Resistant or Refractory CD19 Leukemia and Lymphoma
Conditions: Acute Lymphocytic Leukemia;   Follicular Lymphoma;   Chronic Lymphocytic Leukemia (CLL);   Mantle Cell Lymphoma;   Prolymphocytic Leukemia;   Large Cell Lymphoma
Intervention: Biological: CART-19
4 Recruiting Study Looking at Effectiveness of 131-Tositumomab (Bexxar) Consolidation for Patients With CLL or SLL
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Intervention: Drug: 131TOSITUMOMAB (BEXXAR®)
5 Recruiting Phase I/II Study of B Cell Malignancies Using T Cells Expressing an Anti-CD19 Chimeric Receptor: Assessment of the Impact of Lymphocyte Depletion Prior to T Cell Transfer
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Mantle Cell Lymphoma;   Follicular Lymphoma;   Large Cell Lymphoma
Interventions: Genetic: Anti-CD19-CAR Transduced PBL;   Drug: Aldesleukin;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: PG13-CD19-H3 (anti-CD19-CAR) transduced PBL)
6 Not yet recruiting Lenalidomide and Ofatumumab in Previously Treated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (CLL/SLL)
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Interventions: Drug: Lenalidomide;   Drug: Ofatumumab
7 Recruiting Study of Repeat Intranodal Injection of Memgen's Cancer Vaccine, Ad-ISF35, in Subjects With Non-Hodgkin's Lymphoma (Follicular, Diffuse Large Cell, Mantle Cell, and Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia
Conditions: Non-Hodgkin's Lymphoma;   Follicular Lymphoma;   Diffuse Large Cell Lymphoma;   Mantle Cell Lymphoma;   Small Lymphocytic Lymphoma;   Chronic Lymphocytic Leukemia
Intervention: Biological: ISF35
8 Recruiting Autologous T Lymphocytes Engrafted With a Chimeric Antigen Receptor Targeting the Kappa Light Chain
Conditions: Chronic Lymphocytic Leukemia (B-CLL);   B Cell Non-Hodgkin Lymphoma (B-NHL)
Intervention: Biological: Genetically modified T cells
9 Recruiting Perifosine in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Intervention: Drug: perifosine
10 Recruiting A Phase I/II Study of the Novel Proteasome Inhibitor Bortezomib in Combination With Rituxamib, Cyclophosphamide and Prednisone in Patients With Relapsed/Refractory Indolent B-Cell Lymphoproliferative Disorders and Mantle Cell Lymphoma (MCL)
Conditions: Follicular Lymphoma (Grade I, II, III);   B-Cell Small Lymphocytic Lymphoma;   Chronic Lymphocytic Leukemia;   Marginal Zone Lymphoma;   Waldenstrom's Macroglobulinemia;   Mantle Cell Lymphoma
Intervention: Drug: Bortezomib
11 Not yet recruiting Ofatumumab and Bendamustine for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Intervention: Drug: Ofatumumab and Bendamustine
12 Recruiting First-Line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance.
Conditions: Follicular Lymphoma;   Marginal Zone Lymphoma;   Small Lymphocytic Lymphoma;   Lymphoplasmacytic Lymphoma
Interventions: Drug: Rituximab, Cyclophosphamide, Vincristine, Prednisone;   Drug: Rituximab, Cyclophosphamid, Doxorubicin, Vincristine, Prednisone
13 Recruiting Natural History Study of Monoclonal B Cell Lymphocytosis and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Conditions: B-cell Chronic Lymphocytic Leukemia;   Monoclonal B-Cell Lymphocytosis;   Lymhoma, Small Lymphocytic;   Chronic Lymphocytic Leukemia
Intervention:
14 Recruiting Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma
Conditions: Leukemia;   Lymphoma
Interventions: Biological: filgrastim;   Biological: rituximab;   Drug: carboplatin;   Drug: carmustine;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: ifosfamide;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: radiation therapy;   Radiation: total-body irradiation
15 Recruiting Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, or Relapsed B-Cell Non-Hodgkin Lymphoma
Conditions: Leukemia;   Lymphoma
Interventions: Biological: rituximab;   Drug: cladribine;   Drug: vorinostat;   Other: laboratory biomarker analysis
16 Recruiting Trial of Bendamustine, Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)
Conditions: Chronic Lymphocytic Leukemia;   Non-Hodgkin's Lymphoma
Interventions: Drug: bendamustine and lenalidomide;   Drug: BL-NHL;   Drug: BLR-CLL;   Drug: BLR-NHL
17 Recruiting Cardiac Magnetic Resonance Imaging in Patients With Newly Diagnosed Non-Hodgkin Lymphoma or Hodgkin Lymphoma Receiving Doxorubicin
Conditions: Cardiac Toxicity;   Chemotherapeutic Agent Toxicity;   Lymphoma
Interventions: Drug: doxorubicin hydrochloride;   Procedure: contrast-enhanced magnetic resonance imaging
18 Recruiting Phase I Study Of The Administration Of Peripheral Activated T-Cells Or EBV Specific CTLs Expressing CD19 Chimeric Receptors For Advanced B-Cell Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia (ATECRAB)
Conditions: Non-Hodgkin Lymphoma;   Chronic Lymphocytic Leukemia
Intervention: Biological: autologous CD19CAR T-cells
19 Recruiting Rituximab, Cyclophosphamide, and Pegfilgrastim in Treating Patients With Leukemia or Non-Hodgkin's Lymphoma
Conditions: Leukemia;   Lymphoma
Interventions: Biological: pegfilgrastim;   Biological: rituximab;   Drug: cyclophosphamide
20 Recruiting Study of Repeat Intranodal Injection of Memgen's Cancer Vaccine, Ad-ISF35, in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Intervention: Biological: ISF35

Previous Page Studies Shown (1-20) Next Page (21-40)
Save this search by bookmarking this page.
When you use your bookmark, the search will be performed again on the most recent collection of studies.
RSS Feeds for studies found by your search that were:
  First received in the last 14 days,  
  Last updated (includes received) in the last 30 days
  Download Options




Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services